NTX-301 targets treatment-resistant AML via Hippo pathway in preclinical study
Researchers at MD Anderson Cancer Center have identified that the experimental drug NTX-301 shows promise in treating therapy-resistant acute myeloid leukaemia (AML). The drug works by activating the Hippo pathway, which helps suppress tumor growth and overcome drug resistance.
Why it matters
This discovery offers a potential new therapeutic pathway for patients with high-risk, relapsed AML who have exhausted standard treatment options.
An investigational epigenetic therapy has shown encouraging results against treatment-resistant acute myeloid leukaemia (AML) in preclinical studies from The University of Texas MD Anderson Cancer Center .
The article summarizes scientific research findings in a professional, objective manner.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in